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Introduction: No standard guidelines detailing recommendations
for the selection and treatment for multiple lung nodules with
ground-glass opacity (GGO) have been established. For treatment
decision, we analyzed epidermal growth factor receptor (EGFR)/K-ras
somatic aberrations and pathologic-radiologic correlation in multiple
lung nodules presented as GGO to differentiate multifocal lesions from
intrapulmonary spread.
Methods: Twenty-four patients with multiple lung nodules pre-
sented as GGO were identified to investigate somatic mutations of
EGFR (exon 18–21) and K-ras (codons 2, 13, and 61). This series
included 18 atypical adenomatous hyperplasias (AAH), 15 bronchi-
oloalveolar carcinomas (BAC), and 23 adenocarcinomas (ADC)
obtained from 24 patients.
Results: High frequency of discordant EGFR mutations (17 of 24,
70.8%) could discriminate tumor clonality (18 of 24, 75%) of
multiple lung neoplastic nodules presented as GGO. EGFR muta-
tions were common in AAH (38.9%), BAC (46.7%), and ADC
(39.1%). In case 4, AAH and BAC had different mutational changes,
and in case 10, the BAC lesion contains EGFR mutation that is not
in the invasive ADC. In case 17, the BAC had more mutational changes
than the carcinoma. The pure GGO appearance in the radiologic
examination corresponded preinvasive pathologic change.
Conclusions: This study showed that synchronous BAC and/or
ADC can have different EGFR or K-ras mutational profiles suggest-
ing these lesions arise as independent events rather than intrapulmonary
spread or systemic metastasis. This has significant implication in
staging and treatment. These findings might be a clue to establish
guidelines of the multiple neoplastic lung nodules with GGO.
Key Words: Lung cancer, Multiplicity, Ground-glass opacity (GGO),
Epidermal growth factor receptor (EGFR), Clonality.
(J Thorac Oncol. 2009;4: 1490–1495)
The detection rate of small nodules with ground-glassopacity (GGO) in the peripheral lung is increasing due to
the widespread use of computed tomography (CT) scan-
ning.1,2 GGO lesions are often detected as multiple lesions
(Figure 1), and the incidence of multiple primary lung can-
cers with GGO has significantly increased in approximately
2.6 to 14.1%.3–6 The neoplastic small nodules with GGO
include the full spectrum of preinvasive to invasive lesions
under the putative hypothesis of the sequential development
of lung cancer, atypical adenomatous hyperplasia (AAH),
bronchioloalveolar carcinoma (BAC), or adenocarcinoma
(ADC) with BAC features. Synchronous multifocal lung
nodules with GGO may cause a diagnostic, staging, and
therapeutic dilemma, and the clinical management of such
cases is problematic. No standard guidelines for the selection
and treatment of patients with synchronous multiple nodules
with GGO have been established. The multifocality of lung
nodules may be due to either the dissemination of malignant
cells from a single primary tumor (intrapulmonary spread) or
synchronous development of multifocal independent le-
sions.3–7 The decision as to whether the multiple foci occur
independently or are the result of intrapulmonary metastasis
of a single tumor is of particular interest because intrapulmo-
nary metastasis indicates that the tumor is advanced stage,
and systemic chemotherapy is required than surgical treat-
ment. Although the distinction has important therapeutic and
prognostic implications, it can be sometimes difficult in
surgical pathology practice.7 Histologic features such as sim-
ilar morphology, presence of carcinoma in situ, vascular
invasion, and location are usually considered for the diagno-
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sis of multifocal tumors. Molecular analysis of clonal rela-
tionship between multiple lesions may help the decision of
accurate pathologic stage.7–10 Recently, epidermal growth
factor receptor (EGFR) gene mutation has been reported to
be implicated in the development of pulmonary ADC11–13 and
somatic alterations in EGFR can significantly improve the
clonality assessment of patients with multiple primary lung
cancer.7 EGFR or K-ras mutations were frequently found in
AAH, BAC, and pulmonary ADC.14–22 Furthermore, EGFR
mutations were assumed to have a crucial role in the devel-
opment of pulmonary ADC and to be an initiating event,
because AAH and BAC have been found to have relatively
frequent EGFR mutations.15,16,18–22 Although K-ras mutation
is more frequent in mucinous BAC and ADC without BAC
features,11,21,23 the mutation of K-ras and EGFR genes
showed mutually exclusive pattern,10,14 and thus involvement
of these pathway plays an important role in the development
of lung ADC.
In this study, we examined 56 pulmonary nodules pre-
sented as GGO from 24 patients to analyze mutational status
of the EGFR and K-ras genes and pathologic-radiologic
correlations for clonality assessment. This series included full
spectrum of sequential development, precancerous lesions
(AAH), carcinoma in situ (BAC), and invasive ADC, which
provided better subjects to investigate the early molecular
events of the pulmonary ADC.
PATIENTS AND METHODS
Patients and Specimens
Thirty-two synchronous multiple primary lung nodules
were selected from 685 patients who underwent surgical
resection at the Seoul National University Bundang Hospital,
Korea, from May 2003 to May 2009. Of these, 24 patients
were selected based on having GGO in the preoperative CT
examination. Primary tumors at stage IIIA or greater and
tumors without GGO features in the CT examination were
excluded. These patients were not treated with neoadjuvant
chemotherapy or radiation therapy. This series included 56
lesions (18 AAHs, 15 BACs, and 23 ADCs) detected in the
28 lung specimens resected for cancer with persistent GGO
lesions. This study was approved by the institutional review
board, and all patients provided written informed consent.
Histologic Examination of Tissue Specimens
Paraffin-embedded lung tissue samples were obtained
from the 24 patients. Resected surgical specimens were cut at
3-mm intervals and fixed in 10% buffered formalin. All
sections of the tumor and suspicious lesions were submitted
for microscopic examination. All sections were fixed in
formalin, embedded in paraffin, and stained with hematoxylin
and eosin for histologic examination. Histopathologic diag-
noses of preinvasive and invasive ADCs were based on the
World Health Organization classification24 without informa-
tion of EGFR and K-ras gene mutation. Strict criteria were
applied to the diagnosis of BAC, defined as “an ADC with a
pure bronchioloalveolar growth pattern and no evidence of
stromal, vascular or pleural invasion.” All cases of BAC in
this series were of nonmucinous type. Clinicopathological
information was obtained by reviewing the medical records.
Each lesions was compared with its radiologic findings, and
pathologic-radiologic correlation was performed.
Radiologic Features
Before the postoperative pathologic examinations, two
thoracic radiologists (T.J.K. and K.W.L.) interpreted the CT
images. They were not aware of the preoperative interpreta-
tion of the images or of the intraoperative gross findings.
GGO is defined as hazy increased attenuation of the lung
tissue with preservation of the bronchovascular structures.
The lesions were classified as (1) pure GGO (pGGO), no
solid part of the nodule; (2) mixed GGO (mGGO), GGO with
a solid part occupying less than 50% of the nodule; and (3)
solid GGO (sGGO), GGO with a solid part more than 50%
of the nodules on high-resolution computed tomography
(Figure 1).
FIGURE 1. Multiple ground-glass opacity (GGO) lesions detected by computed tomography (CT) in a 43-year-old woman. A lo-
calized nodule with pure GGO lesions were identified in the right upper lobe and left upper lobe. The pure GGO lesions were diag-
nosed as atypical adenomatous hyperplasia.
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DNA Extraction
Genomic DNA was extracted from paraffin-embedded
tissue. After deparaffinization with xylene, tissue sections
were stained with hematoxylin and eosin, and target lesions
were selectively dissected to minimize any normal tissue
contamination. QIAamp DNA Minikit (Qiagen, Hilden, Ger-
many) was used for genomic DNA isolation according to the
manufacturer’s instructions. Samples were incubated in 200
g of lysis buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA,
and 0.5% sodium dodecyl sulfate) with 40 g of glycogen
and 2 l of proteinase K (20 mg/ml) and incubated at 56°C
overnight. DNA was purified by phenol and chloroform
extraction and dissolved in 20 l Tris-EDTA (10 mM Tris-
HCl pH 8.0 and 1 mM EDTA).
Mutational Analyses of EGFR and K-ras Genes
for Clonality Determination
We analyzed EGFR mutations at exon 18 to 21 and
K-ras mutations at codons 12, 13, and 61 by nested polymer-
ase chain reaction (PCR) and direct DNA sequencing method
as described previously.11,23 PCR amplification was per-
formed in a total volume of 20 L volume containing 10 mM
Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 2.5 mM
deoxynucleotide triphosphates, 0.5 M of each primer, and
0.9 units Taq DNA polymerase (Takara Bio, Shiga, Japan).
After preincubation at 94°C for 2 minutes, DNA was ampli-
fied for 35 cycles under the following conditions: denatur-
ation at 94°C for30 seconds and annealing and elongation at
72°C for 30 seconds. The PCR products were processed with
Big Dye Terminator version 3.1 cycle sequencing kit (Ap-
plied Biosystems, Foster, CA), and sequence data were gen-
erated with the ABI PRISM 3100 DNA Analyzer (Applied
Biosystems). These sequences and chromatographs were
manually confirmed with the EGFR and K-ras reference
sequences by two pathologists (J.H.C. and G.C.). According
to the criteria of Chang et al.,7 the diagnosis of different
clonality was made when different mutations were found in
the multiple nodules. Conversely, monoclonality was diag-
nosed when the tumors showed identical mutation and lack of
the same mutation in the normal lung tissues. When no
mutation was detected in multiple nodules, a diagnosis for
clonality could not be determined.
RESULTS
Patient Characteristics
The clinicopathological characteristics, radiologic find-
ings and EGFR, and K-ras gene mutation analyses are sum-
marized in Table 1. The patients (13 men and 11 women)
were aged 41 to 84 years (median age  60 years) at surgery.
All female patients were nonsmokers. All patients underwent
a unilobectomy with or without wedge resection of another
lobe: a right upper lobectomy in six patients, a right upper
lobectomy with wedge resection of right lower lobe in two, a
right middle lobectomy with wedge resection of right upper
lobe in one, a right lower lobectomy in five, a left upper
lobectomy in five, a left lower lobectomy in two, and a left
lower lobectomy with wedge resection of left upper lobe in
three. The maximum diameter of these nodules presented as
GGO ranged between 3 and 50 mm. The histologic diagnoses
of the 56 nodules were AAH (n  18), BAC (n  15), and
invasive ADC with BAC features (n  23). AAH and BAC
lesions ranged between 3 and 17 mm in diameter. Ten AAH
lesions were concurrent with ADC and/or BAC and four
AAH lesions were detected in one patient and two AAH
lesions in two patients. Twenty patients had synchronous two
lesions, two patients had three lesions, and one patient showed
four and the other one patient had six lesions (Table 1).
Pathologic-Radiologic Correlations
CT appearance of multiple nodules with GGO con-
sisted of 26 pGGOs, 24 mGGOs, and six sGGOs. Regarding
pathologic-radiologic correlation, 16 AAH lesions were pre-
sented as pGGO (Figure 2) and the other two AAH as mGGO.
In the case of BAC, nine lesions were presented as pGGO and
six as mGGO. ADC showed one pGGO, 16 mGGO, and six
sGGO in the CT. Solid portion of the CT appearance and
histologically invasive ADC were a well-matched pair. In the
case of AAH and BAC presented as mGGO, solid portion
was matched to expanded interstitium with fibrosis and/or
inflammatory cell infiltrations.
Mutational Analyses of EGFR and K-ras Genes
EGFR mutations were found in seven cases of AAH
(38.9%), seven cases of BAC (46.7%), and nine cases of
ADC (39.1%). Two BACs (patients 3 and 17) had multiple
EGFRmutations in the same tumor. In case 4, AAH and BAC
had different mutational changes, and in case 10, the BAC
lesion contains EGFR mutation that is not in the invasive
ADC. In case 17, the BAC had more mutational changes than
the carcinoma. According to their appearances in CT, EGFR
mutation was found in 10 pGGO lesions (38.4%), 10 mGGO
lesions (41.6%), and three sGGO lesions (50%) (Table 2).
Seventeen patients had at least one focus that had an EGFR
gene mutation, and none of these patients showed identical
EGFR gene status (Table 3). The remaining seven patients
did not have EGFR mutations in their multiple lesions. In
agreement with previous studies, female patients (81.9%) had
more frequent EGFR mutation than male patients (61.5%),
and never smokers showed more frequent EGFR mutation
(84.6%) than smokers (54.5%).11,15,23 A patient (patient 16)
with wild-type EGFR gene had K-ras gene mutation in one of
the two nodules (Table 3). K-ras gene mutation (G12V) was
found in two ADCs (patients 13 and 16, larger masses), and
one of the K-ras gene mutation was concurrent with EGFR
mutation (patient 13) (Table 1). EGFR or K-ras mutations
were not detected in the normal lung tissue of all patients. For
clonality assessment, the authors classified EGFR or K-ras
gene mutation status into four different distributing patterns
for categorization of multiple nodules: group A, only one
lesion with a mutation; group B, multiple lesions with same
mutations; group C, multiple lesions with different mutations;
and group D, no mutations in the nodules.7 Eighteen patients
(75%) were classified into group A or C and were concluded
as having different clonality of their multiple pulmonary
nodules. The clonality could not be determined in six cases
because there were no EGFR or K-ras gene mutations in their
multiple nodules (Table 3).
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Nucleotide Change Amino Acid Change
1 M 42 Yes 2 BAC mGGO Wild type 17 del 2236–2250 del E746-A750
AAH pGGO Wild type 5 Wild type None
2 M 60 Yes 3 ADC mGGO Wild type 30 del 2240–2254 del L747-T751
ADC mGGO Wild type 3 Wild type None
AAH pGGO Wild type 10 Wild type None
3 M 43 Yes 2 BAC pGGO Wild type 10 Wild type None
BAC pGGO Wild type 5 T2134C and del 2235–2249 F712L and del L747-T751
4 F 41 No 2 BAC mGGO Wild type 10 del 2240–2254 del L747-T751
AAH pGGO Wild type 5 T2573G L858R
5 F 71 No 2 ADC mGGO Wild type 28 Wild type None
BAC mGGO Wild type 15 Wild type None
6 M 78 Yes 2 ADC mGGO Wild type 10 del 2235–2249 del E746-A750
BAC mGGO Wild type 17 Wild type None
7 F 59 No 3 ADC mGGO Wild type 10 del 2240–2254 del L747-T751
BAC mGGO Wild type 7 Wild type None
AAH mGGO Wild type 5 T2573G L858R
8 F 63 No 2 ADC sGGO Wild type 50 Wild type None
BAC pGGO Wild type 10 Wild type None
9 M 58 Yes 2 ADC mGGO Wild type 20 Wild type None
AAH mGGO Wild type 3 Wild type None
10 F 72 No 2 ADC sGGO Wild type 42 Wild type None
BAC pGGO Wild type 7 del 2236–2250 del E746-A750
11 M 69 No 2 ADC sGGO Wild type 20 del 2240–2254 del L747-T751
AAH pGGO Wild type 7 Wild type None
12 M 75 No 6 ADC mGGO Wild type 25 Wild type None
BAC1 pGGO Wild type 8 del 2235–2249 del E746-A750
BAC2 pGGO Wild type 10 Wild type None
BAC3 pGGO Wild type 10 Wild type None
AAH1 pGGO Wild type 5 del 2240–2254 del L747-T751
AAH2 pGGO Wild type 3 Wild type None
13 F 61 No 2 ADC sGGO G12V 50 del 2239–2253 del L747-T751
ADC mGGO Wild type 30 Wild type None
14 M 58 No 2 ADC mGGO Wild type 26 Wild type None
ADC mGGO Wild type 6 Wild type None
15 M 68 Yes 2 ADC mGGO Wild type 20 Wild type None
ADC mGGO Wild type 27 del 2236–2250 del E746-A750
16 M 64 Yes 2 ADC sGGO G12V 32 Wild type None
ADC mGGO Wild type 15 Wild type None
17 F 52 No 2 ADC sGGO Wild type 37 T2573G L858R
BAC pGGO Wild type 15 G2170A and T2573G G724S and L858R
18 M 84 Yes 2 ADC mGGO Wild type 18 Wild type None
AAH pGGO Wild type 6 T2573G L858R
19 M 43 Yes 2 AAH pGGO Wild type 3 Wild type None
AAH pGGO Wild type 2 Wild type None
20 F 67 No 2 AAH pGGO Wild type 7 del 2235–2249 del E746-A750
AAH pGGO Wild type 3 wild None
21 F 43 No 4 AAH pGGO Wild type 7 del 2239–2247 del L747-E749
AAH pGGO Wild type 5 T2573G L858R
AAH pGGO Wild type 5 Wild type None
AAH pGGO Wild type 3 Wild type None
22 M 48 Yes 2 ADC mGGO Wild type 15 Wild type None
BAC pGGO Wild type 7 Wild type None
23 F 59 No 2 ADC mGGO Wild type 23 T2573G L858R
BAC mGGO Wild type 12 del 2236–2250 del E746-A750
24 F 46 No 2 ADC mGGO Wild type 22 del 2236–2250 del E746-A750
AAH pGGO Wild type 5 Wild type None
ADC, adenocarcinoma; BAC, bronchioloalveolar carcinoma; AAH, atypical adenomatous hyperplasia; GGO, ground-glass opacity; pGGO, pure ground-glass opacity; mGGO,
mixed ground-glass opacity; sGGO, solid ground-glass opacity; EGFR, epidermal growth factor receptor; del, deletion; CT, computed tomography.
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DISCUSSION
In this study, we tried to assess clonality of multifocal
neoplastic lung nodules with GGO by analyzing EGFR and
K-ras mutation and correlating pathologic-radiologic find-
ings. Our results showed that EGFR genetic aberrations were
heterogeneous in 70.8% of the patients with distinct foci of
multifocal lung lesions. Seventeen patients showed different
EGFR gene status in their multifocal lesions, and only seven
patients had identical gene status without any mutation. K-ras
gene mutation (G12V) also showed asymmetric fashion in
multiple lesions; however, it is very rare (2 of 56). The
frequency of K-ras mutation is relatively low in this study
compared with other reports.15,16,19,21 Combining both EGFR
and K-ras gene alterations, 75% of the patients had hetero-
geneous genetic status in their multiple lesions. This finding
suggests that each neoplastic GGO lesion would occur inde-
pendently in a subset of multiple lung nodules but that there
remains a possibility of intrapulmonary spread in the remain-
der with wild-type EGFR and K-ras gene in their lesions.
Although EGFRmutation has been known to be implicated in
the early steps of lung ADC development, not all AAH, BAC,
and small ADC have EGFR mutation. In case 4, AAH and
BAC had different mutational changes, and in case 10, the BAC
lesion contains EGFR mutation that is not in the invasive ADC.
In case 17, the BAC had more mutational changes than the
carcinoma. These results raised question regarding the tradi-
tional progression model of AAH to BAC to invasive ADC.
However, similar incidence of EGFR mutation in AAH,
BAC, and ADC supports that AAH and/or BAC with EGFR
mutation might progress into invasive ADC easier than those
without mutation.12
According to pathologic-radiologic correlation, most
cases of the AAH and BAC correspond to pGGO. In other
words, pulmonary neoplastic nodules with GGO have in situ
changes of their own lesions unrelated to their genetic status.
Histologically, presence of in situ lesions of the neoplasm is
preferred to a marker of primary neoplasm rather than me-
tastasis. On the basis of these findings, we suggest that
multifocal lung neoplasms with GGO would be multiclonal
and independent in their origin. Our data, although obtained
from a limited number of patients, provided molecular evi-
dence of a different spectrum of genetic changes for multi-
focal lung nodules with GGO and presence of in situ neo-
plastic changes by pathologic-radiologic correlations. These
findings supported that multifocal neoplastic GGO lesions were
genetically and histologically distinguishable. Genetic heteroge-
neity of multifocal lesions is consistent with the concept of field
cancerization where multiple respiratory epithelia that were
exposed to carcinogens and subsequently underwent neoplastic
FIGURE 2. Aypical alveolar hyperplasia in a 41-year-old woman. A, HRCT shows focal ground-glass opacity (GGO) 5mm in
diameter (white arrow). B, Gross finding of adenomatous hyperplasia (AAH). C, Histologic features of AAH.
TABLE 2. Histologic Types, Radiologic Findings, and EGFR
Genetic Status
Histologic
Type (No.) EGFR Gene
Radiologic Findings (No.)
pGGO (26) mGGO (24) sGGO (6)
AAH (18) EGFR mutant 6 1 0
EGFR wild 10 1 0
BAC (15) EGFR mutant 4 3 0
EGFR wild 5 3 0
ADC (23) EGFR mutant 0 6 3
EGFR wild 1 10 3
EGFR, epidermal growth factor receptor; pGGO, pure ground-glass opacity;
mGGO, mixed ground-glass opacity; sGGO, solid ground-glass opacity; AAH, atypical
adenomatous hyperplasia; BAC, bronchioloalveolar carcinoma; ADC, adenocarcinoma.
TABLE 3. Summary of EGFR and K-ras Gene Combinations
in the Multiple GGOs
No. of Lesion n Case No.
Identical combination (n  6)
EGFR and K-ras wild type 6 5, 8, 9, 14, 19, 22
Different combination (n  18)
EGFR exon19 del and wild type 9 1, 2, 6, 10–12, 15, 20, 24
EGFR exon19 del/K-ras PM (G12V)
and wild type
1 13
EGFR exon19 del and exon
21PM(L858R)
4 4, 7, 21, 23
EGFR exon19 del/exon18 PM (F712L)
and wild type
1 3
EGFR exon 21 PM (L858R) and wild
type
1 18
EGFR exon 21 PM (L858R) and exon
18/21 PM (G724S/L861Q)
1 17
K-ras mutation and wild type 1 16
del, deletion; PM, point mutation; EGFR, epidermal growth factor receptor.
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transformation independently resulted in tumors with similar
morphologic features but distinct clonality.25
However, we could not insist that all the multiple lung
tumors with GGO are of independent origin because the use
of EGFR mutational status as a marker of clonality has some
limitations. In fact, a metastatic tumor may appear different
from the primary tumor at the genetic level because of
progressive accumulation of genetic alteration. Thus, genetic
alterations could be useful as a marker of clonality only in the
early stages of tumorigenesis. Regarding K-ras gene, there
was no mutation in AAH and BAC, and only two invasive
ADC had mutations in our study. This result supported that
K-ras mutation might be a late event in the pathogenesis of
pulmonary ADC.23
In summary, we have shown that EGFR gene hetero-
geneity and pathologic-radiologic correlation in the multifo-
cal neoplastic GGO lesions were helpful to determine clonal
relationship. The constellation of pathologic-radiologic fea-
tures and EGFR mutational analysis would be useful to
establish accurate pathologic stage and subsequent treatment
strategy of multiple pulmonary nodules with GGO.
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